FILTER

Refine your search with the following facets to narrow down your results.

5 Current news of Xantos Biomedicine

Xantos Biomedicine AG has approved funding from the Bavarian Ministry of Economy

01-Dec-2005 - Xantos Biomedicine AG announced that it has been awarded a grant from the Bavarian Ministry of Economic Affairs, Infrastructure, Transport and Technology (=BayStMWIVT) for the expansion of its technology platform. The overall aim of the project, which will run for two years, is to create ...

biology microscopy Qiagen

Xantos Biomedicine and QIAGEN AnnounceCo-Marketing Agreement for RNAi Library with High-Content Cellular Screening System

10-Aug-2005 - Xantos Biomedicine AG and QIAGEN N.V. announced their partnership for co-marketing QIAGEN's proprietary TOM-amidite chemistry based genome-wide RNAi products with Xantos' automated cell-based screening platform, XantoScreen(TM). By combining the capabilities of both companies' platforms customers ...

chemistry Expression gene analysis +7

Xantos Biomedicine AG and Cryptome Pharmaceuticals Ltd collaborate to validate cancer lead

21-Jun-2005 - Xantos Biomedicine AG announced that it has signed a collaboration agreement with Cryptome Pharmaceuticals Ltd, Melbourne, Australia. Xantos has used XantoScreen(TM) technology to discover novel proteins that mediate proliferation of vascular endothelial cells, which potentially play a role in ...

angiogenesis Formation milestone payments +2

Xantos Biomedicine AG, NascaCell and PSF biotech collaborate on cancer drug discovery project

15-Apr-2005 - Xantos Biomedicine AG announced a collaboration with NascaCell IP GmbH and PSF biotech AG. The consortium is set to identify and develop new drugs for the inhibition of tumour angiogenesis, a process by which the growth of blood cells from surrounding tissue into a tumor is induced by a protein ...

angiogenesis education target validation +1

Xantos Biomedicine AG Receives Funding From Sixth EU Framework Program For Angiotargeting Project

25-Feb-2005 - Xantos Biomedicine AG announced that it has been awarded a grant from the European Commission Sixth Framework program for the discovery and validation of new targets and pathways involved in tumor induced blood vessel formation. The overall aim of the project, which will run for four years, is to ...

angiogenesis clinical trials Czech Republic +6